BioNTech and Genmab Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/20/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. ACN
9. AZN
10. SPCX

Go back to BioNTech and Genmab Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates

BioNTech SE (BNTX) Slides on Vaccine Revenue Miss But Consensus Was 'Too High'

August 8, 2022 3:32 PM EDT

BioNTech SE (NASDAQ: BNTX) shares tumbled more than 9% Monday after reporting second-quarter earnings before the open.

The drugmaker posted second-quarter earnings of 6.45 per share on revenue of 3.2 billion. Earnings and revenue fell from the second quarter of 2021, where it reported a profit of 10.77 per share on revenue of $5.3 billion.

"With our strong performance year to date, we believe to be well on track to achieve our previous financial guidance for the ongoing financial year,"... More